Abstract
Purpose: Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, is approved (in the United States and European Union) to treat excessive daytime ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
